Go Pro
NASDAQ:CBIO

Crescent Biopharma Q4 2025 Earnings Report

Crescent Biopharma logo
$16.89 +0.12 (+0.72%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$16.89 0.00 (-0.03%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Crescent Biopharma EPS Results

Actual EPS
-$4.01
Consensus EPS
-$2.22
Beat/Miss
Missed by -$1.79
One Year Ago EPS
N/A

Crescent Biopharma Revenue Results

Actual Revenue
$10.84 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Crescent Biopharma Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Crescent Biopharma's next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules.

Conference Call Resources

Crescent Biopharma Earnings Headlines

Ellie Eunkyung Im Sells 623 Shares of Crescent Biopharma (NASDAQ:CBIO) Stock
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9.1 billion dollars, according to CNBC. Before any Anthropic IPO arrives, one publicly accessible vehicle already lists Anthropic as its largest holding, available through a regular brokerage with no accredited-investor requirement. History showed how fast access tightened once SpaceX became a headline name. Alexander Green of The Oxford Club says this window is open now.tc pixel
Jan Pinkas Sells 658 Shares of Crescent Biopharma (NASDAQ:CBIO) Stock
Joshua Brumm Sells 1,610 Shares of Crescent Biopharma (NASDAQ:CBIO) Stock
Jonathan Mcneill Sells 731 Shares of Crescent Biopharma (NASDAQ:CBIO) Stock
See More Crescent Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Crescent Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Crescent Biopharma and other key companies, straight to your email.

About Crescent Biopharma

Crescent Biopharma (NASDAQ:CBIO) (NASDAQ: CBIO) is a biopharmaceutical company focused on discovering and developing innovative therapies for the treatment of serious diseases. The company’s activities center on research, preclinical development and clinical evaluation of investigational drug candidates.

Crescent Biopharma does not appear to have commercially marketed products. Its pipeline consists of experimental therapies intended to address significant unmet medical needs, although detailed information about specific candidates, therapeutic areas and development stages may be limited in publicly available sources.

The company is headquartered in the United States and serves the biopharmaceutical market through its drug-development programs and potential future partnerships. Additional reliable public information about its history, geographic operations and executive leadership is limited.

View Crescent Biopharma Profile